Literature DB >> 29116943

The PPARG Pro12Ala Polymorphism and 20-year Cognitive Decline: Race and Sex Heterogeneity.

Nancy A West1, Jonathan V Tingle2, Jeannette Simino3, Elizabeth Selvin4, Jan Bressler5, Thomas H Mosley6.   

Abstract

Previous reports suggest race/ethnic and sex heterogeneity in the association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma (PPARG) gene and cognitive decline. Tests of verbal memory, processing speed, and verbal fluency and a composite global Z-score were used to assess cognitive performance longitudinally in a large (n=11,620) biracial cohort of older adults in the Atherosclerosis Risk in Communities Neurocognitive Study from midlife to older age. Linear mixed models were used to estimate associations between the Ala12 allele and cognitive performance over 20 years of follow-up. Heterogeneity was present for rate of cognitive decline as measured by the global Z-score by race, sex, and Ala12 allele status (P=0.01 for 4-way interaction term: race×sex×time×Ala12 carrier status). Stratified analysis showed a significantly increased rate of global cognitive decline over the 20-year follow-up for carriers of the Ala12 allele compared with noncarriers among black male individuals (-0.92 SD decline vs. -0.57 SD; P=0.02) but not among black female, white male, or white female individuals. Decline in global cognitive function among black male Ala12 carriers was primarily driven by decline in verbal memory. Our data underscore the context-dependent association between the Pro12Ala polymorphism and cognitive decline, specifically race/ethnic background and sex.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29116943      PMCID: PMC5938164          DOI: 10.1097/WAD.0000000000000217

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  34 in total

1.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

2.  Progression of mild cognitive impairment to dementia due to AD in clinical settings.

Authors:  Karim Tifratene; Philippe Robert; Asya Metelkina; Christian Pradier; Jean François Dartigues
Journal:  Neurology       Date:  2015-07-01       Impact factor: 9.910

3.  Quality control and quality assurance in genotypic data for genome-wide association studies.

Authors:  Cathy C Laurie; Kimberly F Doheny; Daniel B Mirel; Elizabeth W Pugh; Laura J Bierut; Tushar Bhangale; Frederick Boehm; Neil E Caporaso; Marilyn C Cornelis; Howard J Edenberg; Stacy B Gabriel; Emily L Harris; Frank B Hu; Kevin B Jacobs; Peter Kraft; Maria Teresa Landi; Thomas Lumley; Teri A Manolio; Caitlin McHugh; Ian Painter; Justin Paschall; John P Rice; Kenneth M Rice; Xiuwen Zheng; Bruce S Weir
Journal:  Genet Epidemiol       Date:  2010-09       Impact factor: 2.135

Review 4.  Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.

Authors:  Laurent Gelman; Jérôme N Feige; Béatrice Desvergne
Journal:  Biochim Biophys Acta       Date:  2007-03-16

5.  A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.

Authors:  S S Deeb; L Fajas; M Nemoto; J Pihlajamäki; L Mykkänen; J Kuusisto; M Laakso; W Fujimoto; J Auwerx
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

Review 6.  Dementia and cognitive impairment: epidemiology, diagnosis, and treatment.

Authors:  Julie Hugo; Mary Ganguli
Journal:  Clin Geriatr Med       Date:  2014-06-12       Impact factor: 3.076

7.  Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; J Colleen Karlo; Gary E Landreth
Journal:  J Neurosci       Date:  2012-07-25       Impact factor: 6.167

Review 8.  Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment.

Authors:  Sasanka Chakrabarti; Vineet Kumar Khemka; Anindita Banerjee; Gargi Chatterjee; Anirban Ganguly; Atanu Biswas
Journal:  Aging Dis       Date:  2015-08-01       Impact factor: 6.745

9.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

10.  Impact of differential attrition on the association of education with cognitive change over 20 years of follow-up: the ARIC neurocognitive study.

Authors:  Rebecca F Gottesman; Andreea M Rawlings; A Richey Sharrett; Marilyn Albert; Alvaro Alonso; Karen Bandeen-Roche; Laura H Coker; Josef Coresh; David J Couper; Michael E Griswold; Gerardo Heiss; David S Knopman; Mehul D Patel; Alan D Penman; Melinda C Power; Ola A Selnes; Andrea L C Schneider; Lynne E Wagenknecht; B Gwen Windham; Lisa M Wruck; Thomas H Mosley
Journal:  Am J Epidemiol       Date:  2014-03-13       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.